検索 条件検索
wx_img
Inquiry Form
  1. Home
  2. Seralutinib

Seralutinib

Gossamer Bio and Chiesi Farmaceutici announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. Seralutinib is an inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary hypertension.

3'-Nitroacetophenone
3
CM248294
121-89-1
(S)-3-(1-Aminoethyl)aniline
(S)-3-(1-Aminoethyl)aniline
CM252160
317830-29-8
2,6-dichloropyrazine
2,6-dichloropyrazine
CM104327
4774-14-5
5-methylpyridine-3-carboxylic acid
5-methylpyridine-3-carboxylic acid
CM104017
3222-49-9
2-(3,4-Dimethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
2-(3,4-Dimethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
CM135226
365564-10-9